Table 4.
Efficacy Outcomes of nab-paclitaxel plus gemcitabine in MPACT and the Chinese study
| Parameter | MPACT [7, 8, 19] | Chinese Study |
|---|---|---|
| n | 431 | 83 |
| OS, median, months | 8.7 | 9.2 |
| NLR ≤ 5 | 9.1 | 10.0 |
| NLR > 5 | 5.0 | 8.3 |
| PFS, median, monthsa | 5.5 | 5.5 |
| ORR, %a | 23 | 35 |
| DCR, % | 48 | 55 |
| DOR, median, months | 11.1 | 8.9 |
DCR disease control rate, DOR duration of response, NLR neutrophil-to-lymphocyte ratio, MPACT Metastatic Pancreatic Adenocarcinoma Clinical Trial, ORR overall response rate, OS overall survival, PFS progression-free survival
aIndependently assessed